ABT
Abbott Laboratories
$97.11
Earnings Summary
Revenue | $11895Mn |
Net Profits | $2447Mn |
Net Profit Margins | 20.57% |
Highlights
Abbott Laboratories’s revenue jumped 13.76% since last year same period to $11895Mn in the Q1 2022. On a quarterly growth basis, Abbott Laboratories has generated 3.72% jump in its revenue since last 3-months.
Abbott Laboratories’s net profit jumped 36.48% since last year same period to $2447Mn in the Q1 2022. On a quarterly growth basis, Abbott Laboratories has generated 23.03% jump in its net profits since last 3-months.
Abbott Laboratories’s net profit margin jumped 19.97% since last year same period to 20.57% in the Q1 2022. On a quarterly growth basis, Abbott Laboratories has generated 18.61% jump in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the Abbott Laboratories post its latest quarter earnings
EPS Estimate Current Quarter | 0.91 |
EPS Estimate Current Year | 0.91 |
Highlights
Abbott Laboratories’s earning per share (EPS) estimates for the current quarter stand at 0.91 - a -3.19% fall from last quarter’s estimates.
Abbott Laboratories’s earning per share (EPS) estimates for the current year stand at 0.91.
Key Ratios
Key ratios of the Abbott Laboratories post its Q4 2022 earnings
Return on Assets (ROA) | 0.07 |
Return on Equity (ROE) | 0.19 |
Dividend Per Share (DPS) | 0.47 |
Highlights
Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Abbott Laboratories’s return on assets (ROA) stands at 0.07.
The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Abbott Laboratories’s return on equity (ROE) stands at 0.19.
Abbott Laboratories declared 0.47 dividend per share during the earnings announcement for Q4 2022.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2019-10-31 | 0.84 | 0.84 | 0% |
2019-07-31 | 0.8 | 0.82 | 2.5% |
2020-02-21 | 0.95 | 0.95 | 0% |
2019-05-01 | 0.61 | 0.63 | 3.28% |
Company Information
Abbott Laboratories, headquartered in Chicago, Illinois, was founded in 1888 by a physician named Dr Wallace Calvin. His purpose was to improve people's well-being and help them reach their full potential at different stages of their lives. Founded as a drug formulation company, today, Abbott Laboratories is a worldwide leader in healthcare, medical devices, nutritional products, and pharmaceutical drugs. Even though it reached the shores of India a century ago, it is still regarded as one of the largest healthcare product companies. With a focus on cardiovascular, diagnostic, diabetes, and neuromodulation products, some of its popular brands include Pedialyte, Glucerna, Similac, Ensure, and iStat. Abbott opened its first international office in London in 1907, and currently operates in over 160 countries. Its growth is also a result of strategic acquisitions. Abbott’s recent acquisitions include Kalo Pharma International in 2014, which doubled its brand generic drug portfolio. It acquired Tendyne in 2015 and along with it the company’s minimally invasive mitral valve replacement therapies. Another gem in the crown is the acquisition of Alere in 2016, which gave Abbott access to the largest mail-order diabetic supplier, Arriva Medical. Along with strategic acquisitions, the company is dedicated to gaining a strong competitive advantage. With the onset of COVID-19, the company has developed various antibody tests that have been granted emergency-use authorization. According to Forbes, Abbott Laboratories' fast and low-cost testing methods have expedited the detection of COVID-19 virus. For its 2030 sustainability plan, the company is gearing up to introduce revolutionary products such as BinaxNOW, a COVID-19 test, and FreeStyle Libre, an innovative glucose monitoring device. Abbott’s future plans are centred around providing cutting-edge technologies at affordable prices to even the most vulnerable sections of society. Currently Abbott Laboratories has a market cap of $170.41 Billion. It has a P.E ratio of 24.58. The shares of Abbott Laboratories are trading at $98.46. .
Organisation | Abbott Laboratories |
Headquarters | 100 Abbott Park Road, North Chicago, IL, United States, 60064-6400 |
Employees | 115000 |
Industry | Health Technology |
CEO | Robert Ford |
